91714-93-1

91714-93-1 structure

Name: Bromfenac Sodium
Chemical Name: bromfenac sodium salt
CAS Number: 91714-93-1
Molecular Formula: C₁₅H₁₁BrNNaO₃
Molecular Weight: 356.147
Catalog: Biochemical Inhibitor Neuronal Signaling COX inhibitor
Create Date: 2018-03-22 08:00:00
Modify Date: 2024-01-02 20:41:02
Bromfenac sodium is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac sodium is a brominated non-steroidal anti-inflammatory/analgesic drug (NSAID), and it is commonly used for the research of postoperative inflammation and pain following cataract surgery, and pseudophakic cystoid macular edema (CME)[1][2].

Name	bromfenac sodium salt
Synonyms	Bromfenacsodium BENZENEACETIC ACID, 2-AMINO-3-(4-BROMOBENZOYL)-, MONOSODIUM SALT BENZENEACETIC ACID,2-AMINO-3-(4-BROMOBENZOYL)-, SODIUM SALT (1:1) bromfenac sodium salt {2-amino-3-[(4-bromophényl)carbonyl]phényl}acétate de sodium sodium {2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetate Sodium [2-amino-3-(4-bromobenzoyl)phenyl]acetate Natrium-{2-amino-3-[(4-bromphenyl)carbonyl]phenyl}acetat Bronuck Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, sodium salt (1:1) Bromfenac sodium

Description	Bromfenac sodium is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac sodium is a brominated non-steroidal anti-inflammatory/analgesic drug (NSAID), and it is commonly used for the research of postoperative inflammation and pain following cataract surgery, and pseudophakic cystoid macular edema (CME)[1][2].
Related Catalog	Research Areas >> Inflammation/Immunology Signaling Pathways >> Immunology/Inflammation >> COX
Target	COX-1:5.56 nM (IC50) COX-2:7.45 nM (IC50)
In Vitro	Bromfenac (90 μg/mL; 48 h) inhibits TGF-b1-induced extracellular matrix (ECM) synthesis and myoﬁbroblast activation in HConFs and HPFs[3]. Bromfenac (30-90 μg/mL; 48 h) decreases the protein and mRNA expression levels of FN, COL3, a-SMA, and survivin in a dose-dependent manner in HConFs and HPFs[3]. Bromfenac (30-90 μg/mL; 48 h) declines the phosphorylated protein levels of AKT, ERK1/2, and GSK-3b-S9 with dosage in HPFs and HConFs[3].
In Vivo	Bromfenac (0.0032-3.16%; 100 or 200 μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18h pretreatment time) in rats[2]. Bromfenac (0.032-3.16%; 100 μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats[2]. Bromfenac (0.032-1.0%; 50 μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs[2]. Bromfenac (0.0032-0.1%; 50μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats[2]. Bromfenac (0.32%; 50μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice[2]. Animal Model: Male Sprague-Dawley rats (150-250 g) are injected carrageenan[2] Dosage: 0.0032, 0.01, 0.032, 0.1, 0.32, 1.0, 3.16% (100 or 200 μL) Administration: Rubbed onto the backs before 1-72 h of injected carrageenan Result: Produced significant anti-inflammatory activity when applied 1, 2, and 4 h prior to carrageenan challenge at 0.32%. Applied 1 or 4 h prior to carrageenan challenge was active, but not when applied 24 h (or longer) prior to challenge at 0.2%.
References	[1]. Schechter BA, et, al. Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies. Clin Ophthalmol. 2019 Aug 1; 13:1439-1460. [2]. Nolan JC, et, al. The topical anti-inflammatory and analgesic properties of bromfenac in rodents. Agents Actions. 1988 Aug; 25(1-2): 77-85. [3]. Chen K, et, al. Bromfenac Inhibits TGF-β1-Induced Fibrotic Effects in Human Pterygium and Conjunctival Fibroblasts. Invest Ophthalmol Vis Sci. 2019 Mar 1; 60(4): 1156-1164.

Boiling Point	562.2ºC at 760 mmHg
Melting Point	285ºC
Molecular Formula	C₁₅H₁₁BrNNaO₃
Molecular Weight	356.147
Flash Point	293.8ºC
Exact Mass	354.981995
PSA	83.22000
LogP	2.13590
Appearance	faint yellow to dark yellow
Vapour Pressure	1.77E-13mmHg at 25°C
Storage condition	2-8°C
Water Solubility	H2O: ≥5mg/mL

Symbol	GHS09
Signal Word	Warning
Hazard Statements	H400
Precautionary Statements	P273
Hazard Codes	N
Risk Phrases	50
Safety Phrases	61
RIDADR	UN 3077 9 / PGIII

91713-91-6

~55%

91714-93-1

Literature: Walsh; Moran; Shamblee; Uwaydah; Welstead Jr.; Sancilio; Dannenburg Journal of Medicinal Chemistry, 1984 , vol. 27, # 11 p. 1379 - 1388

Precursor 1
91713-91-6
DownStream 0

91714-93-1	120638-55-3
2749400-35-7	1144097-30-2
81075-52-7	807636-25-5
373645-42-2	30605-57-3
61538-65-6	71376-34-6